Lodoxamide
Names
Preferred IUPAC name
N ,N ′-(2-Chloro-5-cyano-1,3-phenylene)dioxamic acid
Identifiers
ChEMBL
ChemSpider
DrugBank
UNII
InChI=1S/C11H6ClN3O6/c12-7-5(14-8(16)10(18)19)1-4(3-13)2-6(7)15-9(17)11(20)21/h1-2H,(H,14,16)(H,15,17)(H,18,19)(H,20,21)
N Key: RVGLGHVJXCETIO-UHFFFAOYSA-N
N InChI=1/C11H6ClN3O6/c12-7-5(14-8(16)10(18)19)1-4(3-13)2-6(7)15-9(17)11(20)21/h1-2H,(H,14,16)(H,15,17)(H,18,19)(H,20,21)
Key: RVGLGHVJXCETIO-UHFFFAOYAZ
N#Cc1cc(NC(=O)C(=O)O)c(Cl)c(NC(=O)C(=O)O)c1
Properties
C 11 H 6 Cl N 3 O 6
Molar mass
−1
Pharmacology
S01GX05 (WHO
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
Chemical compound
Lodoxamide is an antiallergic pharmaceutical drug. It is marketed under the tradename Alomide in the UK. Like cromoglicic acid it acts as a mast cell stabilizer .[ 1] bufrolin were found to be potent agonists at the G protein-coupled receptor 35 , an orphan receptor believed to play a role in inflammatory processes , pain and the development of stomach cancer .[ 2]
See also
References
^ Avunduk, A. M.; Avunduk, M. C.; Kapicioglu, Z.; Akyol, N.; Tavli, L. (2000). "Mechanisms and comparison of anti-allergic efficacy of topical lodoxamide and cromolyn sodium treatment in vernal keratoconjunctivitis". Ophthalmology . 107 (7): 1333–1337. doi :10.1016/S0161-6420(00)00089-0 . PMID 10890862 . ^ MacKenzie, AE; Caltabiano, G; Kent, TC; Jenkins, L; McCallum, JE; Hudson, BD; Nicklin, SA; Fawcett, L; Markwick, R; Charlton, SJ; Milligan, G (2014). "The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat GPR35" . Molecular Pharmacology . 85 (1): 91–104. doi :10.1124/mol.113.089482 . ISSN 0026-895X . PMC 3868900 PMID 24113750 .
